期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 376, 期 9, 页码 848-855出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1609677
关键词
-
资金
- Assistance Publique-Hopitaux de Paris
- INSERM
Sickle cell disease results from a homozygous missense mutation in the beta-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the complex cellular abnormalities and challenges in achieving effective, persistent inhibition of polymerization of hemoglobin S. We describe our first patient treated with lentiviral vector-mediated addition of an antisickling beta-globin gene into autologous hematopoietic stem cells. Adverse events were consistent with busulfan conditioning. Fifteen months after treatment, the level of therapeutic antisickling beta-globin remained high (approximately 50% of beta-like-globin chains) without recurrence of sickle crises and with correction of the biologic hallmarks of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据